Literature DB >> 20181883

Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis.

Satish K Madala1, John T Pesce, Thirumalai R Ramalingam, Mark S Wilson, Samantha Minnicozzi, Allen W Cheever, Robert W Thompson, Margaret M Mentink-Kane, Thomas A Wynn.   

Abstract

Infection with the parasitic helminth Schistosoma mansoni causes significant liver fibrosis and extracellular matrix (ECM) remodeling. Matrix metalloproteinases (MMP) are important regulators of the ECM by regulating cellular inflammation, extracellular matrix deposition, and tissue reorganization. MMP12 is a macrophage-secreted elastase that is highly induced in the liver and lung in response to S. mansoni eggs, confirmed by both DNA microarray and real-time PCR analysis. However, the function of MMP12 in chronic helminth-induced inflammation and fibrosis is unclear. In this study, we reveal that MMP12 acts as a potent inducer of inflammation and fibrosis after infection with the helminth parasite S. mansoni. Surprisingly, the reduction in liver and lung fibrosis in MMP12-deficient mice was not associated with significant changes in cytokine, chemokine, TGF-beta1, or tissue inhibitors of matrix metalloproteinase expression. Instead, we observed marked increases in MMP2 and MMP13 expression, suggesting that Mmp12 was promoting fibrosis by limiting the expression of specific ECM-degrading MMPs. Interestingly, like MMP12, MMP13 expression was highly dependent on IL-13 and type II-IL-4 receptor signaling. However, in contrast to MMP12, expression of MMP13 was significantly suppressed by the endogenous IL-13 decoy receptor, IL-13Ralpha2. In the absence of MMP12, expression of IL-13Ralpha2 was significantly reduced, providing a possible explanation for the increased IL-13-driven MMP13 activity and reduced fibrosis. As such, these data suggest important counter-regulatory roles between MMP12 and ECM-degrading enzymes like MMP2, MMP9, and MMP13 in Th2 cytokine-driven fibrosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181883      PMCID: PMC3175622          DOI: 10.4049/jimmunol.0903008

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.

Authors:  Thomas A Wynn
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

2.  Transforming growth factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12.

Authors:  Hye-Ryun Kang; Soo Jung Cho; Chun Geun Lee; Robert J Homer; Jack A Elias
Journal:  J Biol Chem       Date:  2007-01-05       Impact factor: 5.157

Review 3.  Matrix metalloproteinases: fold and function of their catalytic domains.

Authors:  Cynthia Tallant; Aniebrys Marrero; F Xavier Gomis-Rüth
Journal:  Biochim Biophys Acta       Date:  2009-04-15

4.  IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways.

Authors:  J A Mengshol; M P Vincenti; C E Brinckerhoff
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

5.  Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme.

Authors:  V Knäuper; H Will; C López-Otin; B Smith; S J Atkinson; H Stanton; R M Hembry; G Murphy
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

6.  Interleukin-13-dependent expression of matrix metalloproteinase-12 is required for the development of airway eosinophilia in mice.

Authors:  Mahmoud A Pouladi; Clinton S Robbins; Filip K Swirski; Meghan Cundall; Andrew N J McKenzie; Manel Jordana; Steven D Shapiro; Martin R Stämpfli
Journal:  Am J Respir Cell Mol Biol       Date:  2003-07-03       Impact factor: 6.914

7.  Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain.

Authors:  Thirumalai R Ramalingam; John T Pesce; Faruk Sheikh; Allen W Cheever; Margaret M Mentink-Kane; Mark S Wilson; Sean Stevens; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Joseph F Urban; Raymond P Donnelly; Thomas A Wynn
Journal:  Nat Immunol       Date:  2007-12-09       Impact factor: 25.606

8.  Essential role of MMP-12 in Fas-induced lung fibrosis.

Authors:  Gustavo Matute-Bello; Mark M Wurfel; Janet S Lee; David R Park; Charles W Frevert; David K Madtes; Steven D Shapiro; Thomas R Martin
Journal:  Am J Respir Cell Mol Biol       Date:  2007-04-19       Impact factor: 6.914

9.  IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs.

Authors:  M G Chiaramonte; L R Schopf; T Y Neben; A W Cheever; D D Donaldson; T A Wynn
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

10.  Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis.

Authors:  Jonathan A Fallowfield; Masashi Mizuno; Timothy J Kendall; Christothea M Constandinou; R Christopher Benyon; Jeremy S Duffield; John P Iredale
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

View more
  67 in total

1.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Authors:  Brijendra Singh; Rajesh K Kasam; Vishwaraj Sontake; Thomas A Wynn; Satish K Madala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis.

Authors:  Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Nabil Z Madhun; Kathryn Niese; Mitchell A Olman; Abram B Stavitsky; Richard Bucala; Laura E Nagy
Journal:  J Leukoc Biol       Date:  2014-11-14       Impact factor: 4.962

Review 3.  Matrix metalloproteinase-12 as an endogenous resolution promoting factor following myocardial infarction.

Authors:  Alan J Mouton; Osvaldo J Rivera Gonzalez; Amanda R Kaminski; Edwin T Moore; Merry L Lindsey
Journal:  Pharmacol Res       Date:  2018-10-28       Impact factor: 7.658

Review 4.  Matrix metalloproteinases in emphysema.

Authors:  Sina A Gharib; Anne M Manicone; William C Parks
Journal:  Matrix Biol       Date:  2018-03-23       Impact factor: 11.583

5.  Gene profiling of the rat medial collateral ligament during early healing using microarray analysis.

Authors:  Connie S Chamberlain; Sabrina H Brounts; David G Sterken; Kevin I Rolnick; Geoffrey S Baer; Ray Vanderby
Journal:  J Appl Physiol (1985)       Date:  2011-05-19

6.  Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.

Authors:  Melissa A Linden; Ryan D Sheldon; Grace M Meers; Laura C Ortinau; E Matthew Morris; Frank W Booth; Jill A Kanaley; Victoria J Vieira-Potter; James R Sowers; Jamal A Ibdah; John P Thyfault; M Harold Laughlin; R Scott Rector
Journal:  J Physiol       Date:  2016-05-27       Impact factor: 5.182

7.  Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression.

Authors:  Ramakrishna Edukulla; Brijendra Singh; Anil G Jegga; Vishwaraj Sontake; Stacey R Dillon; Satish K Madala
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

8.  Hsp90 regulation of fibroblast activation in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Yunguan Wang; Rajesh K Kasam; Debora Sinner; Geereddy B Reddy; Anjaparavanda P Naren; Francis X McCormack; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2017-02-23

Review 9.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

Review 10.  Type 2 immunity in tissue repair and fibrosis.

Authors:  Richard L Gieseck; Mark S Wilson; Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.